USA – Airna, a Cambridge, MA-based biotech company which specializes in RNA editing therapeutics, raised $30M in funding.
The round was led by ARCH Venture Partners, with participation from ND Capital, Fast Track Initiative (FTI), Novalis, and Codon Capital. Led by CEO Kris Elverum, Airna is advancing RNA editing therapeutics. RNA editing targets diseases not accessible through other approaches with a medicine that can be re-dosed and manufactured. Co-founders Thorsten Stafforst (University of Tübingen) and Jin Billy Li (Stanford University), were the first to elucidate a therapeutic approach for precise editing of RNA. The company intends to use the funds to advance a pipeline of RNA editing therapeutics driven by its RNA editing platform, RESTORE+TM. Its first therapeutic program is a product candidate to treat the inherited genetic disease alpha-1 antitrypsin deficiency (AATD), as well as a pipeline of therapeutic candidates to address multiple diseases with high unmet need. Airna also has research operations in Tübingen, Germany. 19/09/2023
